Literature DB >> 2173471

RNase H of human leukemic cells: a new biological parameter in the study of human leukemias (review).

A D Papaphilis1, E F Kamper, S Grammenou, C Kattamis, G A Pangalis.   

Abstract

This article reviews the authors' investigation of the enzyme RNase H (EC 3.1.4.34.) in human leukemic cells and presents the accumulated available data, based on which this enzyme is proposed to serve as a new biological parameter in the study of progression of human leukemias. The introduction gives a brief account of the occurrence, characterization and possible biological role of RNase H in cells and in retroviruses. The results reviewed briefly concern: (1) the development of a new convenient, economic and reliable assay for normal and leukemic blood mononuclear cell RNase H, which is capable of resolving subtle activity differences between samples; (2) the differentiation of RNase H levels between normal and leukemic cells; (3) the correlation of RNase H levels from different leukemia types with the severity of the disease; (4) the correlation of RNase H levels in leukemic cells with clonogenic stages in the clonal differentiation pathway; (5) the predictive potential of a RNase H activity-based parameter (phi) in assessing progression in acute myelocytic leukemia and (6) the possibility of differentiation of the RNase H levels between normal and leukemic cells via regulation of the enzyme activity at the level of antagonistic phosphorylations mediated by cAMP and calmodulin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173471

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.

Authors:  G Grassi; A Forlino; J C Marini
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

2.  Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.

Authors:  Jorge Cortes; Hagop Kantarjian; Edward D Ball; John Dipersio; Jonathan E Kolitz; Hugo F Fernandez; Mark Goodman; Gautam Borthakur; Maria R Baer; Meir Wetzler
Journal:  Cancer       Date:  2011-06-29       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.